TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Extended treatment tested for rare, deadly heart disease
Disease control ENROLLING_BY_INVITATIONThis study follows patients with a rare, inherited heart disease called ATTR amyloidosis with cardiomyopathy to see how safe and effective the drug vutrisiran is over a longer period. It includes about 700 people who either continued taking vutrisiran or switched to it from a sim…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Apr 04, 2026 05:20 UTC
-
Experimental drug aims to halt deadly Heart-Stiffening disease
Disease control OngoingThis study is testing whether the drug patisiran can help people with ATTR amyloidosis, a condition where abnormal proteins build up and stiffen the heart muscle. It involves 360 participants who have heart failure symptoms from this disease. Researchers will measure if the drug …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Experimental drug aims to protect hearts from deadly protein buildup
Disease control OngoingThis study is testing whether an investigational drug called vutrisiran can help people with a serious heart condition called ATTR amyloidosis with cardiomyopathy. The drug is given as an injection under the skin every three months. Researchers are comparing it to a placebo to se…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC